
5.2K
Downloads
52
Episodes
The Life Sciences D’n’A podcast is hosted by AI and data analytics experts and pharma industry veterans Nagaraja Srivatsan and Amar Drawid. They explore the evolving use of AI and data science with innovators working to reshape all aspects of the biopharmaceutical industry from the way new therapeutics are discovered to how they are marketed.
Episodes

Aug 22, 2024
Aug 22, 2024
59 min
Brendan Frey, founder and chief innovation officer of Deep Genomics, sits down with Amar Drawid to discuss how the company is using deep learning to leverage massive RNA biology datasets to drive the development of new therapies.

Jul 25, 2024
Jul 25, 2024
53 min
Ankit Gupta, the head of AI and Senior Director of Machine Learning Research for Ginkgo Bioworks sits down with Amar Drawid to discuss bioengineering beyond healthcare, how the company is using generative AI and large language models to accelerate bioengineering, it expects this to revolutionize the field.

Jun 27, 2024
Jun 27, 2024
1 hr 21 sec
Subodha Kumar, professor of statistics, operations, and data science and the founding director of the Center for Business Analytics and Disruptive Technologies at Temple University’s Fox School of Business, sits down with Amar Drawid to discuss how AI will improve operational efficiency in healthcare, enable mass customization for patients, and free providers up to focus on high-value decision making.

Jun 13, 2024
Jun 13, 2024
1 hr 3 min
Mati Gill, CEO of AION Labs, sits down with Amar Drawid to discuss how the AI venture studio works with its Big Pharma partners to define the biggest drug development hurdles the industry faces; and how it holds challenges to attract academics, entrepreneurs, and life sciences professionals with the best solutions to build new companies.

May 30, 2024
May 30, 2024
1 hr 59 sec
Noam Solomon, co-founder and CEO of Immunai, sits down with Amar Drawid to discuss how the company is using machine learning to take a multi-omics approach to understanding the complexities of the immune system, how it is constructing an atlas of immune cells, and how it is leveraging this to develop the next generation of immunomodulatory drugs.

May 9, 2024
May 9, 2024
58 min
Behavioral health is one area of medicine that has lagged in the move towards precision medicine, in part because of a lack of high-quality evidence to drive decision-making. Holmusk is working to change that by using AI and real-world data to transform mental health care. Eze Abosi, chief growth officer for Holmusk, sits down with Amar Drawid to discuss the need for standardized ways to measure symptoms for behavioral health conditions. They talk about how Holmusk is unlocking much-needed evidence to guide the successful development of new therapies, how its platform technology works, and why he believes it is charting a path for bringing precision medicines to people with mental health conditions.

Apr 25, 2024
Apr 25, 2024
52 min
Healthtech and AI Executive Advisor Christian Hein sits down with Amar Drawid to discuss the use of generative AI in the life sciences, its transformational potential, and the current challenges that need to be addressed.

Apr 11, 2024
Apr 11, 2024
47 min
Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, sits down with Amar Drawid to discuss how her company is leveraging AI to get a deeper understanding of disease biology through the use of transomics. We spoke to Strasser about the challenges studying complex diseases, why it’s critical to have the right data to separate signal from noise, and Pepper Bio's dual strategy for balancing partnerships with its own development pipeline.

Nagaraja Srivatsan
Srivatsan, host of the Life Sciences D'n'A podcast, has more than 30 years of experience in growing businesses in the Digital, Data, AI, Analytics, IT, Product and Operations management areas across several industry verticals. Currently, Srivatsan serves as the CEO of Endpoint Clinical, a global leader in Randomization and Trial Supply Management (RTSM). He is spearheading the next phase of growth, strengthening Endpoint’s position as a trusted partner in accelerating clinical trials and bringing innovative treatments to patients. Additionally, he advises companies, helping them unlock exponential growth opportunities.
